(-)-Epigallocatechin Gallate

For research use only. Not for use in humans.

目录号:S2250 别名: EGCG

(-)-Epigallocatechin Gallate Chemical Structure

CAS No. 989-51-5

(-)-Epigallocatechin Gallate(EGCG) 是从绿茶中分离的一种有效的抗氧化剂Polyphenol flavonoid。抑制telomeraseDNA methyltransferase, 阻滞EGF受体HER-2受体的激活,抑制脂肪酸合成酶以及谷氨酸脱氢酶的活性。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1304.67 现货
RMB 417.04 现货
RMB 577.07 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的(-)-Epigallocatechin Gallate发表文献14篇:

客户使用该产品的4个实验数据:

  • PLoS One 2013 8(8), e69519. (-)-Epigallocatechin Gallate purchased from Selleck.

  • PLoS One 2013 8(8), e69519. (-)-Epigallocatechin Gallate purchased from Selleck.

  • EGCG treatment increases cTnI protein levels in ageing hearts. (A) Western blotting analysis using cTnI and cTnT antibodies. b-Actin was used as protein loading control. (B) A summary of Western blotting results of cTnI. Values are expressed as mean S.D. from four separate experiments. Statistical significance was determined by ANOVA followed by least significant difference (LSD) tests. *P < 0.05 as compared with the 18M + EGCG and 3M groups. EGCG: epigallocatechin-3-gallate

    J Cell Mol Med, 2017, 21(10):2481-2490. (-)-Epigallocatechin Gallate purchased from Selleck.

  • (a) Huh7 cells were incubated with HCVcc of JFH-1 for 2 h before overlaying with 1% agarose dissolved in culture medium or with AR3A anti-E2 neutralizing antibodies, in the presence of 20 μg/ml SZA. EGCG (50 μM) was introduced as a positive control. At 48 h post-infection, infected cells were quantified by IF. Nuclei were stained with DAPI. (b) Numbers of cells per positive colony were determined in 15 foci.

    Sci Rep, 2016, 6:27268.. (-)-Epigallocatechin Gallate purchased from Selleck.

产品安全说明书

Telomerase抑制剂选择性比较

生物活性

产品描述 (-)-Epigallocatechin Gallate(EGCG) 是从绿茶中分离的一种有效的抗氧化剂Polyphenol flavonoid。抑制telomeraseDNA methyltransferase, 阻滞EGF受体HER-2受体的激活,抑制脂肪酸合成酶以及谷氨酸脱氢酶的活性。
靶点
telomerase [4]
()
DNMT [4]
()
HER2 [5]
()
EGFR [5]
()
FASN [6]
()
体外研究

(-)-Epigallocatechin gallate在健康细胞中具有强效抗氧化作用,并降低氧化损伤,作为抗血管生成和抗肿瘤剂,也是肿瘤细胞对化疗应答的调节剂。(-)-Epigallocatechin gallate具有多种抗肿瘤作用,例如抗增殖,抗血管新生,阻断各种癌细胞转化,细胞周期阻滞和抑制肿瘤转移。(-)-Epigallocatechin gallate通过调节多个肿瘤相关的细胞信号通路(调节关键信号蛋白的表达水平,例如核因子-κB, MAPKs和激活蛋白-1,EGFR,IGF,COX-2)影响肿瘤基因的甲基化和配体与膜受体结合发挥抗肿瘤效果。[1] (-)-Epigallocatechin gallate具有免疫调节作用。多种类型的免疫细胞在先天的和适应性免疫系统中都会不同程度受到(-)-Epigallocatechin gallate的影响。在这些作用中,对T细胞的显著作用被反复证明,包括T细胞激活,增殖,分化和细胞因子产生。基于患有自身免疫疾病的动物模型的研究报道表明,绿茶/EGCG处理会使动物的病情好转。[2] (-)-Epigallocatechin gallate具有抗感染活性。(-)-Epigallocatechin gallate的以不同激活模式产生的抗病毒活性在很多种属的病毒中被证实,例如逆转录病毒,正粘病毒科和黄病毒科,还包括重要的人类病原细菌,如人类免疫缺陷病原体,甲型流感病毒和丙型肝炎病毒。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SH-SY5Y cells NH70XWlHfW6ldHnvckBie3OjeR?= NEXRXmNP\XW{b4Dyc5Rm[3Srb36gZYdicW6|dDDi[ZRiNWGveXzvbYQheGWydHnk[UAyNTR{LXnu[JVk\WRidH;4bYNqfHliaX6gbJVu[W5iU1itV3k2YSClZXzsd{Bie3Onc4Pl[EBieyCuYXP0ZZRmKGSnaInkdo9o\W6jc3WgdoVt\WG|ZTygSWM2OD1yLkCzPVg4KM7:TR?= NU\zXodPOTlzM{i4OVk>
human MDA435/LCC6MDR cells MmnqSpVv[3Srb36gZZN{[Xl? MW[xNEDPxE1? NWXSXFZXPSCmYYnz M{noPG1w\HWuYYTpc44hd2ZiUD3ndEApfW6tbn;3ckBwemmpaX6pJJRz[W6|ZnXjeIVlKGmwIHj1cYFvKE2GQUSzOU9NS0N4TVTSJINmdGy|IHHzd4V{e2WmIHHzJJJmfmW{c3nicIUhd2ZicHHjcIl1[XinbDDy[ZNqe3SjbnPlJI1m[XO3cnXkJIF{KEmFNUCg[o9zKHCjY3zpeIF5\WxiYYSgNVAhfU1iYX\0[ZIhPSCmYYnzJIJ6KEOnbHzUbZRmeiB7NjDBdZVmd3W|IHHzd4F6NCCLQ{WwQVAvOTJ{NjFOwG0> MXOyOVk5PTF7NR?=
Sf9 cells M2PLWWZ2dmO2aX;uJIF{e2G7 NFLJOYxKdmirYnn0bY9vKG:oIFjpd|YufGGpZ3XkJIh2dWGwIILlZ49u[mmwYX70JGRPVVRzIHX4dJJme3OnZDDpckBqdnOnY4SgV4Y6KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDEUmEhdWW2aInseJJidnOoZYLhd4Uh[WO2aY\peJkhfXOrbnegOUcu[mmxdHnufYxifGWmIES1MYJxKHWwbXX0bJlt[XSnZDDvdkBp\W2rbXX0bJlt[XSnZDDvcIlod263Y3zlc5Rq\GVic4Xid5Rz[XSnczDhcoQhYzOKXT3B[I9O\XRiYomgcIlyfWmmIIPjbY51cWyuYYTpc44h[2:3boTpcochdWW2aH;kMEBKSzVyPUCuOUDPxE1? NYLVU41oOjV2ME[5OFQ>
human U937 cells MlrGSpVv[3Srb36gZZN{[Xl? NXnSZndYUW6qaXLpeIlwdiCxZjD0[YxwdWW{YYPlJIlvKGi3bXHuJHU6OzdiY3XscJMtKEmFNUC9NUDPxE1? M32xblIzPDF|OES1
human HeLa cells MXnGeY5kfGmxbjDhd5NigQ>? MnHYTY5pcWKrdHnvckBw\iC2ZXzvcYVz[XOnIHnuJIh2dWGwIFjlUIEh[2WubIOgeZNqdmdiNTetRWFVKEOFRzDUR2chSUeFIFHHRUBIXFRvMzegZZMhe3Wkc4TyZZRmKGmwY4XiZZRm\CCob4KgNVUhdWmwczDwdolweiC2bzDlfJRmdnOrb36gdoVi[3Srb36g[o9tdG:5ZXSgZpkh[2:vcH;1coQhf2G|aH;1eEBjgSC|cHnuMZRmdG:vZYLpZ{Bz\XCnYYSgZY1xdGmoaXPheIlwdiCycn;0c4NwdCxiSVO1NF0yNjB6IN88US=> M3PzUVIzPDF|OES1
CHO cells NUT5WFNzS3m2b4TvfIlkyqCjc4PhfS=> M3HycVQ5KGh? NIX0dIdEgXSxdH;4bYNqfHliYXfhbY5{fCCFSF:gZ4VtdHNiZYjwdoV{e2mwZzDPRXRROUJ|IHjhdIxwfHmyZTCxJIFnfGW{IES4JIhzeyCkeTDmcJVwemW|Y3XuZ4Uh[mG|ZXSgR4VtdFSrdHXyMWdtdyCjc4PhfUwhUUN3ME2zMlIh|ryP NHvNOYkzOzN{N{i3Oy=>
MDCK cells M33ndGZ2dmO2aX;uJIF{e2G7 M335OFQh\GG7cx?= NXXmTplMSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhcW6obIXlcppiKEFidnnyeZMhMEFxc4fpcoUwV0hxNUGxOFQ2NzJyMEeoTFFPOSlrIF;oO{Bqdm[nY4Tl[EBqdiCPRFPLJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidnnyZYwhemWybHnjZZRqd25iYX\0[ZIhPCCmYYnzJIJ6KHG3YX70bZRifGm4ZTDSWE1RS1JuIFXEOVA:QC5|IN88US=> M3rDT|IzOTF3NUmx
human HL60 cells M3u3ZnBzd2yrZnXyZZRqd25iYYPzZZk> MXyzJIRigXN? NETjU5BCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZYZ1\XJiMzDkZZl{NCCLQ{WwQVkvPCEQvF2= NIHpcosyQDZ7M{CyNC=>
HSC-T6 cells  MYPGeY5kfGmxbjDhd5NigQ>? M37zTlQ5KGh? NITBUZRCdnSrZnnido91cWNiYXP0bZZqfHliYXfhbY5{fCC{YYSgTHNENVR4IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YheHKxbHnm[ZJifGmxbjDh[pRmeiB2ODDodpMh[nliQoLkWUBqdmOxcoDvdoF1cW:wIHHzd4F6NCCLQ{WwQVkvQSEQvF2= M4HNW|IyPTB2OES4
mouse 3T3-L1 cells NHfVcmdHfW6ldHnvckBie3OjeR?= MnnVTY5pcWKrdHnvckBw\iCJNmDEMY1m\GmjdHXkJG5CTFCKIIDyc4R2[3Srb36gbY4hdW:3c3WgN3Q{NUxzIHPlcIx{NCCLQ{WwQVI2KM7:TR?= NFXtc4syQDNzM{OwPC=>
mouse RAW264.7 cells MmqwSpVv[3Srb36gZZN{[Xl? MXK1JIRigXN? MljETY5pcWKrdHnvckBw\iCUQV7LUE1qdmS3Y3XkJI9{fGWxY3zhd5Rw\2WwZYPpd{BqdiCvb4Xz[UBTSVd{NkSuO{Bk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCWUlHQMZBwe2m2aY\lJI12dHSrLX71Z4xm[XSnZDDj[YxteyCjZoTldkA2KGSjeYOsJGlEPTB;MkmuPEDPxE1? NUDXTYwxOjF2NU[1NlE>
HSC-T6 cells M371dnBzd2yrZnXyZZRqd25iYYPzZZk> NIH1NIRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JJJifCCKU1OtWFYh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6NCCLQ{WwQVI6NjhizszN MUWyOVMzOjR3NR?=
human A431 cells NITPTYpRem:uaX\ldoF1cW:wIHHzd4F6 NUfYVZpZPDhiaB?= MUnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF2M{GgZ4VtdHNib4\ldoV5eHKnc4PpcochTXKkQjDpckB{\XK3bT3mdoVmKG2nZHn1cUBie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgW3NVNTFiYYPzZZktKEWFNUC9N|gh|ryP M16wSlI1PDV4MEC0
human MDA-MB-231 cells MlfNVJJwdGmoZYLheIlwdiCjc4PhfS=> Mn3PNlQhcA>? MVHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[W[2ZYKgNlQhcHK|IHL5JG1VXCCjc4PhfS=> NVPCcWt5OjJ2NUmyNFg>
human HepG2 cells NGHSVJFHfW6ldHnvckBie3OjeR?= NFi4dZozPCCq MXPJcohq[mm2aX;uJI9nKG:uZXnjJIFkcWRvaX7keYNm\CC2cnnncJlk\XKrZHWgc5Zmei2jY3P1cZVt[XSrb36gbY4hcHWvYX6gTIVxTzJiY3XscJMhcW6ldXLheIVlKG[xcjCyOEBpenNicnXsZZRqfmVidH:geY51emWjdHXkJINwdnS{b3y= MWGyNVgzPDZ7MB?=
human HepG2 cells MlHuSpVv[3Srb36gZZN{[Xl? NYjyR|RKOjRiaB?= MlzvRY51cW:6aXThcpQh[WO2aY\peJkhcW5iaIXtZY4hUGWyR{KgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKG:uZXnjJIFkcWRvaX7keYNm\CCUT2Og[4Vv\XKjdHnvckBqdmO3YnH0[YQh\m:{IEK0JIhzeyCkeTDETGNHNUSDIHLhd4VlKG[udX;ybY1mfHKrYzDhd5NigSC{ZXzheIl3\SC2bzD1cpRz\WG2ZXSgZ49vfHKxbB?= MnvZNlE5OjR4OUC=
human Caco-2 cells MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4joXVI2KM7:TR?= NEjJUGU3KGSjeYO= MWTHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDDZYNwNTJiY3XscJMh[XRiMkWgeW0h[W[2ZYKgOkBl[Xm| MXKxPFMzPDd4Mx?=
mouse 3T3 cells NUWzepF2TnWwY4Tpc44h[XO|YYm= Mmr0NU0zOCEQvF2= NF7xXIgyOiCq NVz0UXhsSW62aX3p[5JifG:{eTDhZ5Rqfmm2eTDh[4FqdnO2IGP3bZN{KGGuYnnuc{Bud3W|ZTCzWFMh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4Uhd2ZiY3XscEBvfW2kZYLzJIF1KDFidH:gNlAhfU1iYX\0[ZIhOTJiaILzJIJ6KGK7IIPjdoF1[2hvd3;1coQh[XO|YYm= MkDsNlExQDB4NEK=
human MDA-MB-231 cells NUHzOXBjWHKxbHnm[ZJifGmxbjDhd5NigQ>? M4XmSlI1KGh? NULwUYRiSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHHmeIVzKDJ2IHjyd{BjgSCPVGSgZZN{[Xl? MnntNlI1PTl{MEi=
human Jurkat cells NX\MU5p5TnWwY4Tpc44h[XO|YYm= M3\TO|ExNTV3IN88US=> M3;oSlI1KGh? NX;wfmpCUW6qaXLpeIlwdiCxZjDUUmZidHCqYT3pcoR2[2WmIF7GMYtieHCjQjDhZ5RqfmG2aX;uJIlvKGi3bXHuJGp2emujdDDj[YxteyCjdDCxNEB1dyB3NTD1UUBi\nSncjCyOEBpenNiYomg[Yxm[3S{b4Doc5JmfGmlIH3vZoltcXS7IIPobYZ1KGG|c3H5 NI[4UlUzOTB6ME[0Ni=>
human K562 cells NYTtPJNqTnWwY4Tpc44h[XO|YYm= MmWyNlQhcA>? M{jMRmlv\HWldHnvckBw\iB4NzDrSIEhdGGvaX7pckBz\WOncITvdkBmgHC{ZYPzbY9vKGmwIHj1cYFvKEt3NkKgZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KG[ub4egZ5l1d22ndIL5JIFv[Wy7c3nz NXmxN|VtOjF2M{S2NFM>
human HL60 cells NFXlS3lHfW6ldHnvckBie3OjeR?= MWOyOEBp Mn7zTY5lfWO2aX;uJI9nKDZ5IHvEZUBt[W2rbnnuJJJm[2WydH;yJIV5eHKnc4Ppc44hcW5iaIXtZY4hUEx4MDDj[YxteyCjZoTldkAzPCCqcoOgZpkh\myxdzDjfZRwdWW2comgZY5idHm|aYO= M{PhXlIyPDN2NkCz
human Raji cells MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFfBdHkyOCEQvF2= NXezVZc1PDhiaB?= MnXGS5Jwf3SqIHnubIljcXSrb36gZYdicW6|dDDoeY1idiCUYXrpJINmdGy|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHH0JFExKHWPIHHmeIVzKDR6IHjyd{BjgSC2conwZY4h[my3ZTDiZZNm\CCvaXPyc5Nkd3CrYzDhcoFtgXOrczDpckBxemW|ZX7j[UBw\iC|dYDldo95cWSnIHTpd412fGG|ZR?= NVPQTng1OjF2M{S2NFM>
human PC3 cells NUXqT5hEWHKxbHnm[ZJifGmxbjDhd5NigQ>? NGSwWpAyOC1zMECg{txO NYLIR3Y4PDhiaB?= MWTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyCjdDCxNEB1dyBzMECgeW0h[W[2ZYKgOFghcHK|IHL5JIhmdW:leYTvcYV1emmlIHPlcIwh[2:3boTpcochdWW2aH;k M1HlXFI{QDZ5MU[3
human A431 cells Mmi4SpVv[3Srb36gZZN{[Xl? NHTwdHoyODBizszN NITJSm8yOiCq M3zhb3Jm\HWldHnvckBw\iClbIXzeIVzcW6pIH;mJGdHWC2JUFmgbY4hdGmyaXSgdoFnfHNib3[gbJVu[W5iQUSzNUBk\WyuczDheEAyODBidV2gZYZ1\XJiMUKgbJJ{KGK7IHPvcoZw[2GuIH3pZ5Jwe2OxcHnjJIFv[Wy7c3nz NYnQXG8zOjR2NU[wNFQ>
human SKBR3 cells MlLCSpVv[3Srb36gZZN{[Xl? MkfGNlAx|ryP NYrDUnJlOzBibXnudy=> MX3Ec5dvemWpdXzheIlwdiCxZjDFdoJDOiCycn;0[YlvKGW6cILld5Nqd25iaX6gbJVu[W5iU1vCVlMh[2WubIOgbY4he2W{dX2g[pJm\SCvZXTpeY0h[XRiMkCwJJVOKGGodHXyJFMxKG2rboOgZpkhcW2vdX7v[ox2d3Knc3PlcoNmKHO2YXnubY5oNWKjc3XkJINwdm[xY3HsJI1q[3Kxc3PvdIlkKGGwYXz5d4l{ MXKyOFQ2PjByNB?=
human 293T cells MYDGeY5kfGmxbjDhd5NigQ>? MWm1NEDPxE1? MkT2NVIhcA>? NGTHR3BKdmirYnn0bY9vKG:oIFTZVmsySSCrbjDoeY1idiB{OUPUJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCJTFmxJJRz[W6|Y4LpdJRqd25iYXP0bZZqfHliYYSgOVAhfU1iYX\0[ZIhOTJiaILzJIJ6KGS3YXytcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6 NH3mdVQzOjF3NE[2OC=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
β-catenin / p-AKT / Cyclin D1; 

PubMed: 28693189     


EGCG inhibits β-catenin, p-Akt and cyclin D1 expression in MDA-MB-231 cells. MDA-MB-231 cells were treated with EGCG for 24 h. (A) β-catenin protein expression was analyzed by western blotting. (B) p-Akt and cyclin D1 protein expression were analyzed by western blotting. β-actin was used as a loading control. Each value represents the mean ± standard error of the mean of three independent experiments. EGCG, epigallocatechin gallate; p-, phosphorylated.

p-MAPK / MAPK ; 

PubMed: 30233784     


Effects of EGCG on IGF-I-induced phosphorylation of (A) p44/p42 MAP kinase in MC3T3-E1 cells. The cells were pretreated with various doses of EGCG for 60 min, and then stimulated by 10 nM IGF-I or vehicle for (A) 5 min. Western blot analysis was performed using antibodies against phospho-p44/p42 MAP kinase, p44/p42 MAP kinase. The histograms show quantitative representation of the levels of IGF-I-induced phosphorylation determined from laser densitometric analysis of three independent experiments. EGCG, (−)-epigallocatechin gallate; IGF-I, insulin-like growth factor-I; MAP, mitogen-activated protein.

Notch1 / Notch2 ; 

PubMed: 28443100     


Human primary macrophages derived from peripheral blood mononuclear cells (PBMCs) cultured with autologous serum were pretreated with EGCG (50 μg/mL) for 30 min and exposed to LPS (200 EU/mL) for 3 h. Cell lysates from time course experiments of EGCG treatment were analyzed by western blotting and probed with a Notch1/2 antibody  

28693189 30233784 28443100
Growth inhibiton assay
Cell proliferation ; 

PubMed: 23525843     


The percent EGCG that inhibits the proliferation of colorectal cancer cells at different concentrations. Notes: The x-axis and y-axis are the time after treatment and percentage of EGCG that inhibits the proliferation of colorectal cancer cells at different concentrations. Eight experiments were performed for each treatment, and the inhibition rate of cell proliferation was tested for, using a single factor analysis of variance. Abbreviation: EGCG, epigallocatechin gallate; h, hour.

Cell viability; 

PubMed: 28693189     


Effect of EGCG on the viability of MDA-MB-231 cells. MDA-MB-231 cells were treated with various concentrations of EGCG for 24 h. MTT assay was used to detect the viability of the cells. The optical density value of the untreated cells was regarded as 100%. Each value represents the mean ± standard error of the mean of three independent experiments. EGCG, epigallocatechin gallate.

23525843 28693189

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 Ethanol 83 mg/mL warmed (181.07 mM)
DMSO 72 mg/mL warmed (157.07 mM)
Water 23 mg/mL warmed (50.17 mM)

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 458.37
化学式

C22H18O11

CAS号 989-51-5
储存条件 粉状
溶于溶剂
别名 EGCG

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03928847 Recruiting Drug: Epigallocatechin-3-gallate (EGCG) Idiopathic Pulmonary Fibrosis University of California San Francisco|National Heart Lung and Blood Institute (NHLBI) July 1 2018 Early Phase 1
NCT02779361 Completed Dietary Supplement: Green tea Healthy Volunteers|Doping in Sports Parc de Salut Mar|World Anti-doping Agency January 2016 Phase 1
NCT02577393 Enrolling by invitation Drug: EGCG|Drug: mLDG Lung Neoplasms|Esophagitis|Prevention & Control|Epigallocatechin Gallate Shandong Cancer Hospital and Institute April 2015 Phase 2
NCT02580279 Enrolling by invitation Drug: EGCG|Drug: placebo Breast Neoplasms|Dermatitis|Prevention & Control|Epigallocatechin Gallate Shandong Cancer Hospital and Institute December 2014 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

Telomerase Signaling Pathway Map

相关Telomerase产品

Tags: 购买(-)-Epigallocatechin Gallate | (-)-Epigallocatechin Gallate供应商 | 采购(-)-Epigallocatechin Gallate | (-)-Epigallocatechin Gallate价格 | (-)-Epigallocatechin Gallate生产 | 订购(-)-Epigallocatechin Gallate | (-)-Epigallocatechin Gallate代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID